Panaxium

Panaxium is pioneering a novel therapeutic approach to neuro-recovery following brain injury. Its platform integrates a soft, biocompatible 'iontronic' brain-machine interface designed to communicate precisely with neural tissue, alongside advanced neuroimaging and AI to map patient-specific functional networks and plan interventions. The company is in the preclinical to early clinical stage, having secured non-dilutive funding and strategic partnerships, with the goal of turning everyday activities into assisted recovery exercises. Its vision is to move beyond symptom management to enable true healing and restoration of function.

Integrated precision neuro-recovery platform combining a soft, biocompatible 'iontronic' brain-machine interface for precise neuromodulation with a proprietary MRI and AI-assisted analysis suite for patient-specific functional network mapping and therapy planning.

Panaxium competes in the broader brain-computer interface and neuromodulation space, but its focus on temporary implantation for therapeutic healing of acquired brain injury is a distinct niche. It faces competition from chronic BCI companies (e.g., Synchron, Neuralink) and neuromodulation device firms, but its integrated 'healing platform' approach is unique.